Lilly, Novo Approvals Shift S&P 500 Winners Today!

Publication date: 2026-04-07

Introduction

Concrete regulatory decisions and sizable M&A moves this week are reshaping the near‑term outlook for large-cap pharmaceutical names in the S&P 500. The U.S. Food and Drug Administration cleared Eli Lilly’s oral GLP‑1, Foundayo, and approved Novo Nordisk’s once‑weekly basal insulin, Awiqli — two approvals that carry immediate commercial and competitive implications. At the same time, strategic acquisitions and licensing deals (notably Lilly’s purchase of Centessa and Biogen’s acquisition of Apellis) are altering revenue trajectories and investor sentiment. Below we summarize the facts, quantify the implications, and highlight the most actionable investor takeaways.

Major FDA approvals: direct catalysts for large-cap stocks

Foundayo — Lilly’s first oral GLP‑1

The FDA approved Foundayo (orforglipron), a once‑daily oral GLP‑1 receptor agonist, based on ATTAIN trial data reporting roughly 11–12% mean weight loss versus about 1–2% for placebo. As the first oral agent in this class, Foundayo represents a disruptive alternative to established injectables and could broaden patient adoption by removing the injection barrier. For Lilly (an S&P 500 heavyweight), the approval is a near-term commercial uplift and a structural advantage in the obesity/diabetes franchise.

Awiqli — Novo Nordisk’s once‑weekly basal insulin

Novo Nordisk secured approval for Awiqli (insulin icodec), a once‑weekly basal insulin supported by the ONWARDS Phase III program. Awiqli’s differentiated dosing schedule could shift adherence dynamics and capture a portion of patients currently managed with daily basal insulins. While Novo Nordisk is not U.S.-listed, the approval strengthens competitive pressure on S&P 500 insulin and GLP‑1 players and underpins investor rotation into companies with durable diabetes franchises.

M&A and licensing: how deals are altering S&P 500 valuations

Lilly’s bolt-on moves: Centessa and AI partnerships

Lilly agreed to acquire Centessa (roughly $6.3 billion upfront; $7.8 billion potential), acquiring clinical-stage CNS assets such as cleminorexton and accelerating its neuro pipeline. Combined with earlier AI-focused licensing with Insilico (about $115 million upfront, up to $2.75 billion), Lilly is expanding both late‑stage and discovery engines. For investors, these deals signal management’s willingness to pay for near-term assets and technology that could sustain revenue growth beyond core endocrinology franchises.

Biogen buys Apellis; other strategic consolidations

Biogen’s purchase of Apellis for about $5.6 billion brings marketed drugs Empaveli and Syfovre onto Biogen’s balance sheet and strengthens near‑term revenue visibility. Such acquisitive activity among S&P 500 constituents is reducing binary clinical risk across portfolios and creating predictable cash flows that can re-rate valuations short term.

Other concrete developments with S&P 500 implications

GSK, AbbVie, and Merck items to watch

GSK received EMA acceptance for bepirovirsen’s MAA in chronic hepatitis B — a regulatory milestone that matters for European-focused revenues. AbbVie reported positive Phase III results for Skyrizi in Crohn’s (about 55% remission in the AFFIRM induction study), strengthening its GI franchise. Separately, takeover talks reported between Merck and Revolution Medicines (valued near $28–32 billion) underscore continued appetite for transformative oncology assets among S&P 500 pharma buyers.

AI-driven alliances: Insilico and Infinimmune deals

Big‑pharma licensing agreements with AI discovery platforms (Insilico/Lilly and Infinimmune/Merck) involve meaningful upfronts and multibillion-dollar potential milestones. These deals are practical evidence that large S&P 500 players are investing to accelerate early discovery and diversify pipelines — a structural theme that can support premium valuations.

Investor implications: where value and risk lie

Short-term catalysts

• Commercial launches and uptake data for Foundayo and Awiqli — watch prescription growth, payer coverage, and early sales figures.
• Integration signals and near‑term revenue guidance revisions from Biogen and Lilly post‑acquisitions.
• Follow-up regulatory decisions (EU approvals, label language) that materially affect addressable populations.

How to position in S&P 500 healthcare

These developments favor large-cap names with diversified franchises and strong commercialization infrastructure. Investors looking for lower volatility exposure may prefer S&P 500 pharma incumbents that gain immediate revenue from acquisitions (Biogen/Apellis) or durable franchise expansion (Lilly). Conversely, short‑term speculators can target event-driven windows around launch metrics and quarterly guidance updates.

Conclusion

This week produced tangible, near‑term drivers for S&P 500 pharmaceutical stocks: FDA approvals that change treatment convenience and adherence (Foundayo, Awiqli), plus acquisitive moves that de‑risk revenue streams (Lilly/Centessa, Biogen/Apellis). For investors, the path to alpha is now less about speculation and more about monitoring measurable launch performance, integration execution, and regulatory follow‑through. Those metrics will determine who captures durable market share and who faces increased competitive pressure.